Hero Image HCP Hero Image HCP Hero Image HCP
For on-demand treatment of acute hereditary angioedema (HAE) attacks
Be prepared for an HAE attack. Be prepared with BERINERT.

BERINERT is the only on-demand treatment offering:

15 min Icon

Median onset of laryngeal
attack relief: 15 minutes

Median onset of laryngeal attack relief: 15 minutes

Plus Sign
Icon C1 INH

Single dose,
rapid uptake*

Plus Sign
Icon Pediatrics

Approved use
in pediatrics

More than 50% of people with HAE may experience a laryngeal attack in their lifetime1

Following self-administration of BERINERT for laryngeal HAE attacks, advise patients to immediately seek medical attention.
In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.2
BERINERT is the only C1-INH approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of HAE in adults and pediatric patients.
Get your patients started on BERINERT
Prescribe BERINERT and empower them to self-administer at the first sign of an HAE attack.
Get started

Have additional questions?

Connect with CSL Behring Medical Affairs to find additional information and ask questions.

References: 1. Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036. 2. Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54:1552-1561. 3. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429. 4. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):264-274.

You are now leaving the current website.

Do you want to continue?

No Yes